PPR-127 - Effect of Metformin on the risk of post-COVID-19 condition among individuals with overweight and obesity in the United Kingdom: A population-based retrospective cohort study

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: PPR-127
• By: CHAICHANA, Ubonphan (UCL School Of Pharmacy, United Kingdom)
• Co-author(s): Ms Ubonphan Chaichana (UCL School Of Pharmacy, London, United Kingdom)
  Dr Kenneth Man (UCL School Of Pharmacy, London, United Kingdom / Laboratory of Data Discovery for Health (D24H), Hong Kong Special Administrative Region, China / Centre for Medicines Optimisation Research and Education, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom / Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China)
  Dr Chengsheng Ju (UCL School Of Pharmacy, London, United Kingdom / Institute of Cardiovascular Science, University College London, London, United Kingdom)
  Professor Li Wei (UCL School Of Pharmacy, London, United Kingdom / Laboratory of Data Discovery for Health (D24H), Hong Kong Special Administrative Region, China / Centre for Medicines Optimisation Research and Education, University College London Hospitals National Health Service (NHS) Foundation Trust, London, United Kingdom)
  Dr Janine Makaronidis (Centre for Obesity Research, Rayne Institute, Department of Medicine, University College London, London, United Kingdom / National Institute of Health and Care Research, University College London Hospitals Biomedical Research Centre, London, United Kingdom / Department of Diabetes and Metabolism, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom)
  
• Abstract:

  Background: A secondary analysis of the COVID-OUT trial showed that starting metformin within three days of a COVID-19 diagnosis and continuing it for 14 days reduced the incidence of post-COVID-19 condition (PCC) by 41% in overweight and obese individuals, compared to a placebo. However, these findings were limited to individuals aged 30–85..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login